WILSONS DISEASE: A MULTISYSTEMIC CONDITION CAUSED BY ABERRANT COPPER ACCUMULATION, INCLUDING ITS PATHOGENESIS, EPIDEMIOLOGY, PRESENT STATE, AND EFFECTIVE TREATMENT APPROACHES

Yash Srivastav*, Jyotsana Shrivastava, Madhaw Kumar, Nutan Shrivastava, Nikita Sharma, Anubha Dhuriya, Mohammad Aqil Siddiqui

Wilson's disease (WD) is an uncommon autosomal recessive copper metabolism disorder brought on by ATP7B gene mutations. This gene produces the ATP7B protein, a crucial transmembrane copper-dependent ATPase that is mostly expressed in hepatocytes. ATP7B is necessary for the liver's two primary vital copper metabolism routes, which are (1) copper incorporation into ceruloplasmin (Cp) and (2) hepatocyte biliary excretion of excess copper. Copper will gradually and pathologically build up, mostly in the liver but also in other tissues, including the cornea and central nervous system, whenever ATP7B is lost or its function is diminished in hepatocytes. Wilson's disease affects roughly one in 30,000 individuals. Typically, symptoms start to appear between the ages of five and thirty-five. It bears the name of British neurologist Samuel Wilson and was initially reported by German pathologist Friedrich Theodor von Frerichs in 1854. According to the World Health Organisation, between 10 and 30 million people worldwide suffer from Wilson disease, with an incidence of 1 in 10,000 to 30,000 persons. 2–5 Orphanet estimates that the prevalence varies by geographic location, ranging from 1 to 9 per 100,000 people worldwide. According to the World Health Organisation (WHO), between 30 and 100 cases of WD occur worldwide. In a study of hepatobiliary spectrum illnesses in North India, WD impacted 7.6% of cases. Despite the absence of epidemiological data on neurological WD in India, a South Indian WD clinic reported 15–20 new cases of WD annually. Wilson's disease is characterised by a wide range of clinical signs and symptoms, from acute liver failure and severe neurological symptoms to asymptomatic liver involvement. The recommendations provide customised diagnostic methods for particular presentations, such as severe failure of the liver. Wilson disease patients require treatment for the rest of their lives. Acute liver failure may result after stopping treatment. Blood and urine tests are routinely performed by doctors to assess the effectiveness of treatment. Wilson disease is treated with two chelating agents: trientine (Syprine) and penicillamine (Cupramine, Depen). Copper is eliminated from the body by these medications. Management of Wilson Disease: The American Association for the Study of Liver Diseases' 2022 Practice Guidance on Wilson Disease offers a modern method for WD diagnosis and treatment. It takes the place of earlier AASLD guidelines on the same subject that were released in 2008. Being listed in an NLM database does not mean that NLM or the National Institutes of Health agree with or approve the information. A mutation in the ATP7B gene causes Wilson's disease (WD), an autosomal recessive condition that mostly affects the liver and brain and results in impaired copper metabolism. Wilson's disease (WD) pathophysiology, aetiology, diagnosis, treatment, and consequences are all covered.